ATARA Biotherapeutics (ATRA) Misses Q2 EPS by 10c

ATARA Biotherapeutics (NASDAQ: ATRA) reported Q2 EPS of ($0.32), $0.10 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $630 thousand versus the consensus estimate of $2.55 million.

For earnings history and earnings-related data on ATARA Biotherapeutics (ATRA) click here.

You May Also Be Interested In

• JPMorgan Upgrades Aviva Plc (AV/:LN) (AIVAF) to Overweight
• Citi sees Birkenstock EPS beat, guidance lift on FX and lower share count
• JPMorgan Assumes Bravura Solutions Ltd (BVS:AU) at Neutral